SCR-LIP-000556 · Claim · machine-readable JSON →
This narrative review describes estrogen pathway dysregulation in lipedema, with an increased ER-alpha/ER-beta ratio in affected lower-body subcutaneous adipose tissue, local upregulation of aromatase CYP19A1, and estrogen-induced ZNF423 promoting preadipocyte differentiation via PPARG, alongside AKR1C1 mutations raising progesterone and stimulating adipogenesis.
This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- very low (GRADE)
- Evidence
- 1 source(s)
- Answers
- 0 question(s)
- Dates
- 2026-11-17 → 2026-11-17
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17
Evidence over time
Evidence (1)
- Lipedema: pathophysiological insights and therapeutic strategies — An update for dermatologists (2026) ✓ verified — consistent · review · 2026 · reading confidence: high
“Estrogen pathway dysregulation: increased ER-alpha/ER-beta ratio in subcutaneous adipose tissue of affected lower-body regions drives upregulation of lipid/glucose uptake genes, lipolysis inhibition, and mitochondrial dysfunction; aromatase CYP19A1 upregulated locally; estrogen-induced ZNF423 promot”
The review synthesizes hormonal/estrogenic mechanisms (ER ratio, aromatase, ZNF423, AKR1C1) implicated in lipedema pathophysiology, providing affirmative mechanistic evidence that hormonal factors influence the condition, though as a narrat
Context (PECO)
Answers these questions
- Not yet linked to a question.
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-11-17 — created · auto-ingested for SQ-LIP-000035
- 2026-11-20 — consolidated · SQ-LIP-000035: evidence moved to SCR-LIP-000643